Teva announces FDA approval of ProAir RespiClick® (albuterol sulfate) inhalation powder
Teva announced the FDA has approved ProAir RespiClick® (albuterol sulfate) Inhalation Powder for treatment or prevention of bronchospasm in children 4 to 11 years of age with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. April 29, 2016